Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Curi RMB Capital LLC

Curi RMB Capital LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.1% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 17,483 shares of the medical research company’s stock after purchasing an additional 1,000 shares during the period. Curi RMB Capital LLC’s holdings in Thermo Fisher Scientific were worth $10,814,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of TMO. Wealthstream Advisors Inc. bought a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $207,000. Zions Bancorporation N.A. boosted its holdings in Thermo Fisher Scientific by 8.6% in the third quarter. Zions Bancorporation N.A. now owns 11,455 shares of the medical research company’s stock worth $7,086,000 after purchasing an additional 907 shares during the period. KBC Group NV increased its stake in Thermo Fisher Scientific by 52.2% during the third quarter. KBC Group NV now owns 376,193 shares of the medical research company’s stock valued at $232,702,000 after purchasing an additional 128,968 shares during the last quarter. Huntington National Bank boosted its holdings in shares of Thermo Fisher Scientific by 4.6% in the 3rd quarter. Huntington National Bank now owns 132,375 shares of the medical research company’s stock valued at $81,883,000 after buying an additional 5,855 shares during the period. Finally, Peak Asset Management LLC raised its stake in Thermo Fisher Scientific by 9.2% during the third quarter. Peak Asset Management LLC now owns 3,403 shares of the medical research company’s stock worth $2,105,000 after acquiring an additional 286 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TMO. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. UBS Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Stifel Nicolaus decreased their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Finally, Royal Bank of Canada decreased their price objective on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Stock Down 1.6 %

Shares of TMO stock opened at $533.02 on Friday. The firm’s fifty day moving average price is $589.87 and its two-hundred day moving average price is $583.04. Thermo Fisher Scientific Inc. has a 1 year low of $463.99 and a 1 year high of $627.88. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $203.88 billion, a P/E ratio of 33.42, a PEG ratio of 3.58 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the previous year, the company earned $5.69 earnings per share. The firm’s revenue for the quarter was up .2% on a year-over-year basis. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be issued a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the transaction, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at $7,134,197.76. The trade was a 13.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This trade represents a 1.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,150 shares of company stock worth $20,651,865 over the last quarter. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.